GSK blood cancer drug reapproved by EU regulator
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
Related reading
US health agency reapproves GSK blood cancer drug after new trial
FDA gives go-ahead to UK drugmaker’s multiple myeloma treatment Blenrep
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
GSK hails promising trial results for hepatitis B treatment
Drug could provide a cure for condition that affects more than 250mn people
Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
EU trims exclusivity window for new drugs
Cheaper generics will be allowed on to market a year earlier to curb costs